Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations

Lianna Ishihara, Liling Warren, Rachel Gibson, Rim Amouri, Suzanne Lesage, Alexandra Dürr, Meriem Tazir, Zbigniew K. Wszolek, Ryan J. Uitti, William C. Nichols, Alida Griffith, Nobutaka Hattori, David Leppert, Ray Watts, Cyrus P. Zabetian, Tatiana M. Foroud, Matthew J. Farrer, Alexis Brice, Lefkos Middleton, Faycal Hentati

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Background: The G2019S mutation is the most common pathogenic substitution in the leucine-rich repeat kinase 2 (LRRK2) gene, which has recently been identified in familial and sporadic Parkinson disease (PD). Objectives: To report the clinical characteristics of PD patients with homozygous LRRK2 6055G>A (G2019S) mutations and to compare them with previously published descriptions of heterozygous patients. Design: Descriptive clinical report from an international consortium of studies. Subjects: Patients with familial PD and homozygous LRRK2 mutations included 23 Tunisians, 2 Algerians, 2 US patients, 1 Canadian, and 1 Moroccan. Results: There were no observable differences between the homozygote and heterozygote phenotypes. Conclusions: Parkinson disease related to LRRK2 is characterized by typical clinical features, and the similarities between patients with homozygous and heterozygous mutations do not support a gene dosage effect.

Original languageEnglish (US)
Pages (from-to)1250-1254
Number of pages5
JournalArchives of neurology
Issue number9
StatePublished - 2006

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations'. Together they form a unique fingerprint.

Cite this